Background {#Sec1}
==========

Red blood cells and plasma harbour carbon dioxide (CO~2~) in the form of dissolved CO~2~, bicarbonate, and carbamino compounds which are in equilibrium with each other \[[@CR1]\]. The sum of all components is expressed as total CO~2~ (tCO~2~).

CO~2~ accumulation causes hypercarbia which may be a challenge in intensive care unit (ICU) patients. It has propagated a more extensive use of extracorporeal techniques to enable ultra-protective ventilation in acute respiratory distress syndrome or to avoid intubation in patients with severe exacerbation of chronic obstructive lung disease \[[@CR2]\]. Although renal replacement therapy (RRT) is advocated to generate small amounts of CO~2~ due to the red blood cell passing through the filter \[[@CR3]\], the net effect is a removal of CO~2~ in an intermittent hemodialysis (IHD) model with acetate \[[@CR3], [@CR4]\] This CO~2~ extraction of 41 ml/min seemed to correlate with a deficit of 46 ml/min in expired CO~2~ \[[@CR5]\]. Different methods have been explored to increase the removal of CO~2~ in effluent by increasing pH with THAM or NaOH but it seemed too complex and too dangerous to be used in humans. \[[@CR6]\] Extraction reached up to 120 ml/min in an in vitro model of IHD \[[@CR7]\]. "CO~2~ loss" induced by RRT may become clinically relevant as mean expired CO~2~ in ICU patients is 180 ml/min \[[@CR8]\]. Continuous RRT (CRRT) is progressively supplanting intermittent dialysis in the ICU. CRRT is hemodynamically well-tolerated, may provide easier control of metabolic alterations and fluid overload, and is associated with less chronic kidney disease in the post-ICU phase \[[@CR9]--[@CR11]\]. The impact of CRRT on CO~2~ metabolism is remarkably poorly documented. In addition, trisodium citrate - the preferred anticoagulant for CRRT- acts as a weak acid \[[@CR12]\]. This will alter the Henderson-Hasselbalch equation, disrupt the balance between the different CO~2~ forms, and thus potentially influence CO~2~ extraction during CRRT.

We designed a study to better understand CO~2~ and O~2~ extraction during CRRT. Based on obtained data, formulas were constructed to assess CRRT-related CO~2~ clearance at the bedside.

Methods {#Sec2}
=======

A prospective study was performed in critically ill patients undergoing continuous veno-venous hemofiltration (CVVH). The study was approved by the Ethical Committee of the University Hospital Brussels (reference BUN 143201731636) and registered at <https://clinicaltrials.gov> (reference NCT03314363). Informed consent was obtained from the patient or a legal representative.

CVVH was performed with the Prismaflex®(Lund, Sweden) Baxter® device equipped with a Prismaflex® Baxter®, AN69 surface treated (ST) filter of 1.5 square meter (Meyzieu, France). Prismocitrate®18/0 (Sondalo, Italy) Baxter® was used as predilution and Prismocal® B22 (Sondalo, Italy) Baxter® or NaCl 0.9% as postdilution fluid. Dosing and postdilution fluid use were initiated and adapted according to an implemented standard CVVH protocol.

Inclusion and exclusion criteria are listed in Additional file [1](#MOESM1){ref-type="media"}. Blood samples were taken at 5 different sample points (SP) (Fig. [1](#Fig1){ref-type="fig"}). SP were located at the distal end of the arterial dialysis catheter lumen (SP1); between citrate predilution infusion port and filter (SP2); directly after the filter (SP3); at the effluent conduit (SP4); proximal to the venous dialysis catheter lumen (SP5). At every SP, pH, HCO~3~-, tCO~2~, pCO~2~, pO~2~, hemoglobin (Hb) and Hb saturation were measured using a blood gas analyzer \[ABL90 Flex®, Radiometer(Bronshoj, Denmark)\]. Subsequently, citrate predilution was stopped and replaced for at least 20 min by NaCl 0.9% at similar flow. Blood gas analysis was repeated according to the same protocol.Fig. 1Schematic representation of CVVH set-up with location of sampling points and ports of fluid infusion. Pre = predilution fluid, Post = postdilution fluid, AC = de-aeration chamber

O~2~ content (tO~2~) was calculated as Hb x Hb saturation × 1.35 \[[@CR1]\]. CO~2~ (V̇CO~2~) and O~2~ flow (V̇O~2~) at the specific SP were calculated by multiplying the set fluid flow (Q) on CVVH with respectively tCO~2~ and tO~2~. Results were adjusted from mmol to ml by using Boyle's gas law: pV = nRT (p: pressure of the gas, V: volume of gas, n: amount of substance of gas, R: gas constant, T absolute temperature of the gas). The average air pressure recorded by the Belgian national weather institute was applied and ambient temperature was measured. "Transmembrane" (i.e before and after the filter) V̇CO~2~ was calculated by subtracting V̇CO~2~ at SP3 from V̇CO~2~ at SP2. "Transmembrane tCO~2~" was calculated in the same way.

tCO~2~ of bicarbonate fluid was 22 mmol/l, converted by gas law to ml/l depending on ambient conditions, and calculated in ml/min based on the flow set on CVVH. When bicarbonate was used, the "expected V̇CO~2~ at SP5" was calculated by adding the calculated V̇CO~2~ of the postdilution fluid to the V̇CO~2~ at SP3.

Relevant parameters such as CRRT settings were collected tobe used in a predictive equation.

Statistical analysis {#Sec3}
--------------------

Data were analyzed using Prism Graphpad® version 7(La Jolla, USA). As data sets contained 18 values at the most, normality was not assessed. Data are expressed as mean ± standard deviation. Wilcoxon matched-pairs signed rank test was performed to evaluate significance of difference between 2 data sets. Friedman test was used when more data sets were compared. Differences in measured data, V̇CO~2~ and V̇O~2~ between SP were evaluated.

V̇CO~2~ in the effluent (SP4) was compared with "transmembrane V̇CO~2~". "Expected V̇CO~2~ at SP5" was compared with V̇CO~2~ at SP5. A subgroup analysis was performed to compare the influence of citrate on CO~2~ extraction by the filter by comparing "transmembrane tCO~2~" with and without citrate.

Results {#Sec4}
=======

Summary of patient characteristics are depicted in Table [1](#Tab1){ref-type="table"}. CVVH settings of patients are provided in Additional file [2](#MOESM2){ref-type="media"}. Predilution citrate was not replaced by NaCl 0.9% in 2 patients because pre-existing hypercoagulability could compromise filter function.Table 1patient characteristicsPatients (n)10Age (years)68.7 ± 11.3Gender (male/female)8/2BMI (kg/m^2^)29.8 ± 7.3APACHE II27.1 ± 9.0Reason for admission: Medical8 Surgical2Receiving controlled or assisted ventilation at day of study (n)9Mean CVVH settings in all series of blood gas analysis (ml/h) Bloodflow9000 ± 0 Predilution1750 ± 447 Postdilution444 ± 170 Effluent flow2380 ± 175Data are presented as means ± standard deviation

Comparison of V̇CO~2~ {#Sec5}
--------------------

V̇CO~2\ (SP1)~ was higher than V̇CO~2\ (SP5)~ and V̇CO~2\ (SP2)~ \[111.3 ± 8.1 ml/min vs. respectively 87.4 ± 14.6 ml/min (*p* \< 0.01) and 110.5 ± 9.6 ml/min (*p* = 0.03)\]. V̇CO~2~ dropped significantly between SP2 and SP3 \[from 110.5 ± 9.6 ml/min to 84.5 ± 6.5 ml/min (p \< 0.01)\]. V̇CO~2~ at SP4 (26.0 ± 5.8 ml/min) and transmembrane V̇CO~2~ at SP4 (24.2 ± 2.6 ml/min) were not statistically different (*p* = 0.39).

Results for NaCl 0.9% postdilution were plotted in Fig. [2](#Fig2){ref-type="fig"}. Patients receiving postdilution NaCl 0.9% exhibited higher V̇CO~2\ (SP1)~ than V̇CO~2\ (SP5)~ \[109.8 ± 7.1 ml/min vs. 81.7 ± 5.8 ml/min (*p* \< 0.01)\] and a 1.3 ml/min difference between V̇CO~2\ (SP3)~ and V̇CO~2\ (SP5)~ \[83.0 ± 4.9 ml/min vs. 81.7 ± 5.8 ml/min (*p* = 0.01)\].Fig. 2Evolution of CO~2~ flow in the extracorporeal blood circuit during NaCl 0.9% postdilution. Sample point 4 was not included as it is not situated in the extracorporeal blood circuit and is not suited to represent evolution of V̇CO~2~ in the blood. When difference between data was statistical significant different, this was marked with an asterisk

No statistical analysis was performed when bicarbonate was used as postdilution fluid as it only consisted of 3 data sets. A 21.7 ml/min difference was noted between V̇CO~2~ at SP5 (116.1 ± 9.7 ml/min) and "expected V̇CO~2~ at SP5" (94.4 ± 9.9 ml/min) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Expected CO~2~ flow in sample place 5 versus CO2 flow at sample place 5 during bicarbonate containing Prismocal B22® postdilution. When difference between data was statistical significant different, this was marked with an asterisk

Comparison of tCO~2~ {#Sec6}
--------------------

Results are given in Fig. [4](#Fig4){ref-type="fig"}. tCO~2~ at SP2 (25.5 ± 2.8 mmol/l), SP3 (25.0 ± 2.6 mmol/l) and SP4 (25.1 ± 2.6 mmol/l) were not statistically different (*p* = 0.51). tCO~2~ decreased significantly between SP1 and SP2 from 30.6 ± 2.3 mmol/l to 25.5 ± 2.8 mmol/l (p \< 0.01). At all SP, tCO~2~ consisted of CO~2~ in gas form (pCO~2~) and HCO~3~- (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Evolution of tCO~2~ at different sample points in all series of blood gas analysis. Sample point 5 was not included as it is influenced by bicarbonate Prismocal B22 postdilution fluid. When difference between data was statistical significant different, this was marked with an asteriskFig. 5Distribution of pCO~2~ and HCO~3~- at different sample points in all series of blood gas analysis. Sample point 5 was not included as it is influenced by bicarbonate Prismocal B22 postdilution fluid

Effect of citrate vs. no-citrate predilution on transmembrane tCO~2~ {#Sec7}
--------------------------------------------------------------------

Patients in whom citrate could not be withdrawn were excluded from analysis. ΔtCO~2~ between SP2 and SP3 was not different in the citrate vs no-citrate group (*p* = 0.21) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Effect of citrate on transmembrane tCO~2~

Comparison of V̇O~2~ {#Sec8}
-------------------

V̇O~2~ at SP1, SP2, SP3 and SP5 was respectively 10.6 ± 3.7 ml/min,10.9 ± 3.9 ml/min, 10.3 ± 3.8 ml/min, and 10.9 ± 3.7 ml/min. V̇O~2~ at SP4 was 0 ml/min as effluent contains no Hb. V̇O~2\ (SP1)~ and V̇O~2\ (SP5)~ were not different (*p* = 0.33) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Evolution of O~2~ flow in the extracorporeal blood circuit in all series of blood gas analysis. Sample point 4 was not included as it is not situated in the extracorporeal blood circuit and is not suited to represent evolution of V̇O~2~ in the blood

Development of formulas {#Sec9}
-----------------------

The above findings allow to propose following formulas:$$\documentclass[12pt]{minimal}
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As tCO~2~ is similar at SP2, SP3 and SP4, the equation becomes:$$\documentclass[12pt]{minimal}
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By assuming that$$\documentclass[12pt]{minimal}
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When \[tCO~2~\]~SP2~ is substituted in the above formula \[\*\], it becomes$$\documentclass[12pt]{minimal}
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Discussion {#Sec10}
==========

We present the first study that prospectively evaluated CO~2~ and O~2~ behavior in patients undergoing CVVH. The main finding was that a substantial amount of 26.0 ml/min CO~2~ was removed in the effluent. This represents approximately 14% of the average expired V̇CO~2~ measured in ICU patients \[[@CR8]\] and thus could be clinically relevant. Furthermore, CO~2~ removal during CVVH was found to be 80% lower than previously observed in an in vitro hemodialysis model. This is explained by the almost threefold higher blood flow rate used in this model as compared to our CVVH setting \[[@CR7]\]. V̇CO~2~ before and after predilution (Δ V̇CO~2~ between SP1 and SP2) was statistically different, probably because the set CVVH fluid flow at these SP did not correspond with real fluid flow \[[@CR9]\]. Blood analysis also depended on "snapshot" sampling which might not exactly reflect average flow. However, this difference did not seem clinically relevant compared with average expired V̇CO~2~ (\< 1%). CO~2~ flow was then divided between the effluent and the blood running to the de-aeration chamber (SP3 and SP4). The CO~2~ flow in the effluent correlated with V̇CO~2~ loss in the blood after passing the filter \[$\documentclass[12pt]{minimal}
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In patients receiving postdilution NaCl 0.9%, 1.3 ml/min of CO~2~ was removed in the de-aeration chamber. This is a very small quantity compared to the average V̇CO~2~ in ICU patients \[[@CR8]\]. Thus, CO~2~ removal was almost entirely determined by transmembrane filtering and measurable in the effluent. However, when postdilution bicarbonate was used, the expected V̇CO~2~ did not correspond with the calculated V̇CO~2~ in the blood before it re-entered the body. Several assumptions may explain this observation. First, measurements may be incorrect when CO~2~ fails to enter red blood cells after being infused in the postdilution fluid into the extracorporeal circuit. Second, tCO~2~ was calculated and not measured. Formulas for these calculations may not be applicable in a non-physiological state of bicarbonate-induced blood alkalinization. Studies measuring blood tCO~2~ are needed to elucidate this problem.

As suggested by in vitro hemodialysis, CO~2~ is removed in the effluent in gas form and as HCO~3~- \[[@CR7]\]. The CO~2~ concentration or tCO~2~ is the driving force for this removal as it remains constant in effluent and in the blood passing through the filter \[tCO~2(SP2)~ = tCO~2(SP3)~ = tCO~2(SP4)~\]. By adding predilution fluid, tCO~2~ decreased between SP1 and SP2.

Citrate anticoagulation did not influence tCO~2~ extraction. Only the short term effect of citrate upon CO~2~ removal was evaluated as an influencer of acid-base homeostasis. Over a longer time period, citrate could possibly affect CO~2~ clearance because it preserves membrane porosity better than heparin. tCO~2~ in blood passing through the CVVH circuit decreased as it was diluted by bicarbonate-free solutions. CVVH had no impact on V̇O~2~ because values remained constant at the different SP.

Based on previous findings, different formulas were constructed to calculate CO~2~ removal by CVVH in a clinical setting with the use of only one blood gas analysis in the extracorporeal circuit at a preexisting sample point. As these are the first data that were acquired in a CVVH setting, formulas could not be compared to data from other articles \[[@CR7]\]. Further studies need to confirm our findings.

Several limitations of our study must be emphasized. First, despite the high number of analyses per patient, the sample size remains small and future studies in more patients are needed to confirm our results. Second, assumptions were made based on "snapshot" blood gas analysis. Continuous monitoring would be more precise. Third, fluid flows as set on CVVH may not correlate with real flow \[[@CR13]\]. In-circuit flow measurements may be a better option. Finally, it remains to be determined whether the removed CO~2~ influences expired CO~2~.

Conclusion {#Sec11}
==========

A significant amount of CO~2~, both as gas and bicarbonate and measurable in the effluent, is removed during CVVH under citrate anticoagulation. Pre-filter tCO~2~ is the major determinant for CO~2~ removal. Citrate does not influence CO~2~ elimination. To a certain extent, bicarbonate fluids influence blood gases but data are too limited to permit relevant conclusions. Oxygen flow is not influenced by CVVH. CO~2~ removal by CVVH in bicarbonate-free conditions can be calculated by multiplying effluent or blood flow with CO2 content at a preexisting sample point. Their clinical relevance requires confirmation.

Additional files
================

 {#Sec12}

Additional file 1:Inclusion and exclusion criteria that were used during the study. (DOCX 15 kb) Additional file 2:CVVH settings and postdilution fluid per patients. (DOCX 14 kb)
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